Antioxidant paraoxonase 1 activity in the metabolic syndrome

被引:126
作者
Sentí, M
Tomás, M
Fitó, M
Weinbrenner, T
Covas, MI
Sala, J
Masiá, R
Marrugat, J
机构
[1] Inst Municipal Invest Med, Lipids & Cardiovasc Epidemiol Unit, E-08003 Barcelona, Spain
[2] Hosp Josep Trueta, Girona 17007, Spain
[3] Univ Pompeu Fabra, Barcelona, Spain
关键词
D O I
10.1210/jc.2003-030648
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Paraoxonase (PON1) is an antioxidant enzyme closely associated with high-density lipoproteins. Low PON1 has been shown in oxidative stress-associated processes such as dyslipidemia, diabetes mellitus, advancing age, and smoking. Indeed, oxidative stress is related to the degree of insulin resistance, a key component of the metabolic syndrome. Therefore, the possible relationship between PON1 activity and the metabolic syndrome was investigated. From 1364 randomly recruited subjects, 285 were found to have the metabolic syndrome, according to the guidelines published by the National Cholesterol Education Program, Adult Treatment Panel III. PON1 activity, lipid peroxides, and PON1 codon 192 genotypes, which strongly modulate PON1 activity, were determined. Serum PON1 activity levels were found to be significantly lower, and lipid peroxide concentrations significantly higher, in subjects with the metabolic syndrome compared with unaffected subjects ( P = 0.033 and < 0.001, respectively). Study subjects showed a significant decreasing trend in PON1 activity levels and a significant increasing trend in lipid peroxide concentrations, with the increase in the number of metabolic disturbances. No differences in the prevalence of PON1 codon 192 genotypes were found among the categories of metabolic abnormalities. In conclusion, a greater degree of severity of the metabolic syndrome is associated with a progressively worse antioxidant/ oxidant balance, which is consistent with increased oxidative stress and lower antioxidant PON1 enzymatic capacity.
引用
收藏
页码:5422 / 5426
页数:5
相关论文
共 37 条
[1]   Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants [J].
Aviram, M ;
Rosenblat, M ;
Billecke, S ;
Erogul, J ;
Sorenson, R ;
Bisgaier, CL ;
Newton, RS ;
La Du, B .
FREE RADICAL BIOLOGY AND MEDICINE, 1999, 26 (7-8) :892-904
[2]   Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[3]   Serum paraoxonase after myocardial infarction [J].
Ayub, A ;
Mackness, MI ;
Arrol, S ;
Mackness, B ;
Patel, J ;
Durrington, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) :330-335
[4]   LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects [J].
Barbieri, M ;
Bonafè, M ;
Marfella, R ;
Ragno, E ;
Giugliano, D ;
Franceschi, C ;
Paolisso, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :222-225
[5]  
Cao HB, 1999, J LIPID RES, V40, P133
[6]   Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? [J].
Evans, JL ;
Goldfine, ID ;
Maddux, BA ;
Grodsky, GM .
DIABETES, 2003, 52 (01) :1-8
[7]   Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey [J].
Ford, ES ;
Giles, WH ;
Dietz, WH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03) :356-359
[8]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[9]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[10]  
Grundy SM, 1999, AM J CARDIOL, V83, p25F